Last reviewed · How we verify
Lifitegrast Ophthalmic
Lifitegrast Ophthalmic, marketed by Tauber Eye Center, is an established product in the ophthalmic therapeutic segment. The key composition patent for Lifitegrast Ophthalmic is set to expire in 2028, providing a clear period of market exclusivity. The primary risk is the potential increase in competition following the patent expiry.
At a glance
| Generic name | Lifitegrast Ophthalmic |
|---|---|
| Also known as | Xiidra |
| Sponsor | Tauber Eye Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- This is a Single Center, Open-label Prospective Study to Evaluate the Effect of Xiidra® (Lifitegrast Ophthalmic Solution 5.0%) on Tear Film Biomarkers in Dry Eye (PHASE4)
- A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease (PHASE2)
- Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications
- A Study to Assess the Long-Term Safety of Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination in Subjects With Dry Eye Disease (PHASE3)
- A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory Treatment (PHASE4)
- Lifitegrast Eye Drops in Healthy Subjects：Phase I Study (PHASE1)
- A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease (PHASE1, PHASE2)
- A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lifitegrast Ophthalmic CI brief — competitive landscape report
- Lifitegrast Ophthalmic updates RSS · CI watch RSS
- Tauber Eye Center portfolio CI